Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer

Karacin C., Sunar V., Urakci Z., YILMAZ A., Ayhan M., Ersoy M., ...Daha Fazla

Future oncology (London, England), cilt.20, sa.4, ss.207-214, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 4
  • Basım Tarihi: 2024
  • Doi Numarası: 10.2217/fon-2023-0763
  • Dergi Adı: Future oncology (London, England)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.207-214
  • Anahtar Kelimeler: bevacizumab, low grade, ovarian cancer, peritoneum, serous, tuba
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Aim: To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded. Results: The median age of 51 patients was 56 (range: 33-75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI: 9.1-22.6) and median overall survival was 42.5 months (95% CI: 37.2-47.8). Conclusion: Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.